Pirfenidone inhibits bladder cancer xenograft growth in mice by regulating regulatory T cells.
10.12122/j.issn.1673-4254.2025.07.18
- Author:
Hongbo ZHANG
1
;
Mengyu YAN
1
;
Jiandong ZHANG
1
;
Peiwang SUN
1
;
Rui WANG
1
;
Yuanyuan GUO
1
Author Information
1. Department of Urology, First Affiliated Hospital of Bengbu Medical University, Bengbu 233040, China.
- Publication Type:Journal Article
- Keywords:
bladder cancer;
immune microenvironment;
pirfenidone;
regulatory T cells
- MeSH:
Animals;
Urinary Bladder Neoplasms/drug therapy*;
Mice;
T-Lymphocytes, Regulatory/metabolism*;
Mice, Inbred C57BL;
Interleukins/metabolism*;
Interleukin-10/metabolism*;
Cell Line, Tumor;
Interleukin-2/metabolism*;
Xenograft Model Antitumor Assays;
Female
- From:
Journal of Southern Medical University
2025;45(7):1513-1518
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To investigate the inhibitory effect of pirfenidone (PFD) on growth of bladder cancer xenograft and its regulatory effect on Treg cells in tumor-bearing mice.
METHODS:Thirty-two C57BL/6 mice bearing ectopic bladder tumors were randomized into control and PFD groups (n=16). In PFD group, PFD was administered orally at the daily dose of 500 mg/kg, and tumor growth and survival of the mice were monitored. After treatment for 21 days, the tumors and vital organs were harvested for analysis. Immunohistochemistry was used to assess CD3, CD4, CD8, and FOXP3 expressions in the tumors. Flow cytometry and RT-qPCR were used to analyze the percentage of CD4⁺CD25⁺FOXP3⁺ Treg cells and IL-2, IL-10, and IL-35 expressions in the tumors and spleens; organ damage of the mice was examined with HE staining.
RESULTS:Compared with the control group, the PFD-treated mice exhibited significantly lower tumor growth rate with smaller tumor volumes at day 21, along with improved survival at day 28. Immunohistochemistry revealed no significant differences in the infiltration of CD3⁺ and CD8⁺ cells between the two groups, but the percentages of CD4⁺ and FOXP3⁺ cells were significantly lower in the tumors of PFD-treated mice. Flow cytometric analysis confirmed a decrease in CD4⁺CD25⁺FOXP3⁺ Treg cells in the tumors from PFD-treated mice, which also had reduced expression levels of IL-2, IL-10 and IL-35 mRNAs in the tumors. No significant differences were found in Treg cell populations or cytokine expressions in the spleen tissues between the two groups. HE staining showed obvious organ damage in neither of the groups.
CONCLUSIONS:PFD inhibits bladder cancer growth and enhances survival of tumor-bearing mice possibly by suppressing Treg cells in the tumor microenvironment.
